Application of butyrolactone compound in preparation of medicine for treating renal clear cell carcinoma
By extracting and purifying 2-O-methylbutyrolactone, a butyrolactone compound, from the marine fungus Aspergillus pyrolyticus, and combining it with sorafenib, the problem of sorafenib resistance in clear cell renal cell carcinoma was solved, significantly enhancing the therapeutic effect and synergistically inhibiting tumor growth.
CN122097347APending Publication Date: 2026-05-29NINGBO UNIV
5 Cites 0 Cited by
Patent Information
- Application Number
- CN202610551070.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-04-24
- Publication Date
- 2026-05-29
AI Technical Summary
Technical Problem
In the current technology, clear cell renal cell carcinoma has serious resistance to sorafenib, resulting in poor treatment effects, and there is a lack of drugs that can enhance the sensitivity of clear cell renal cell carcinoma to sorafenib treatment.
Method used
The 2-O-methylbutyrolactone compound, obtained by extracting and purifying rice culture through fermentation of rice culture by the marine fungus Aspergillus ustus, was used in combination with sorafenib to enhance treatment sensitivity.
Benefits of technology
It significantly improves the sensitivity of clear cell renal cell carcinoma to sorafenib treatment, synergistically enhances anti-tumor effects, delays the onset of drug resistance, effectively inhibits tumor growth, and improves treatment outcomes.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention discloses an application of a butyrolactone compound in preparation of a medicine for treating renal clear cell carcinoma, which is characterized in that the structural formula of the compound is shown as I, and the application of the compound in preparation of a medicine for resisting renal clear cell carcinoma tumors and in preparation of a medicine for improving the therapeutic sensitivity of renal clear cell carcinoma sorafenib. The preparation method comprises the following steps: carrying out fermentation culture on marine fungi to obtain a fermentation product, soaking the fermentation product in ethyl acetate, extracting to obtain a crude extract, and sequentially carrying out normal-phase medium-pressure column chromatography separation, reversed-phase medium-pressure column chromatography separation and semi-preparative reversed-phase high-performance liquid chromatography separation and purification on the crude extract to obtain the marine fungus extract. The pharmaceutical composition has the advantages that the sensitivity of the renal clear cell carcinoma to sorafenib treatment can be remarkably enhanced, tumor growth can be effectively inhibited, and the occurrence of drug resistance can be delayed.
Need to check novelty before this filing date? Find Prior Art